Momotaro-Gene
Biotherapeutics company advancing gene therapies for cancer treatment with a focus on relapsed malignant pleural mesothelioma
About Momotaro-Gene
Momotaro Gene is a clinical-stage biotherapeutics company specializing in the development of novel gene therapies aimed at treating cancer. The company is currently conducting a Phase 2 clinical trial at Baylor College of Medicine in Houston, Texas, to evaluate the efficacy, safety, and tolerability of its lead therapeutic candidate, MTG201, in combination with the PD-1 inhibitor nivolumab. This trial targets patients with relapsed malignant pleural mesothelioma who have not responded to standard platinum-based chemotherapy. The primary goal is to assess the treatment's efficacy in this patient group. Momotaro Gene has previously completed two Phase 1 trials of MTG201, which showed promising safety and tolerability in patients with malignant mesothelioma and localized prostate cancer. The company's business model focuses on advancing its gene therapy pipeline through clinical trials, with the potential to generate revenue through partnerships and licensing agreements. Momotaro Gene operates in the biopharmaceutical market, serving patients with aggressive cancers that have limited treatment options. The company's approach combines gene therapy with immunotherapy to explore synergistic anti-tumor effects, addressing a critical need for new treatment options in relapsed cancer forms.
Source: Dealroom company dataNews
Open roles
Momotaro-Gene in the Okayama ecosystem
The Momotaro-Gene office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Nissay Capital
BiGEN
Kyorin Pharmaceutical
Series B and later2 investors entered at this stage
Nippon Venture Capital
Iyogin Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Momotaro-Gene on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Momotaro-Gene on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.